UC San Diego researchers describe the underlying signaling pathway that results in pulmonary arterial hypertension and a novel monoclonal antibody therapy that blocks the abnormal blood vessel formation characterizing the disease.
Targeting Molecular Pathway that Causes Pulmonary Arterial Hypertension
